![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Ramatroban (KARE 101), a dual blocker of thromboxane and prostanoid receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, and evidence for rapid relief of dyspnea and hypoxemia in COVID-19 pneumonia.
Lead Product(s): Ramatroban
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KARE 101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 05, 2022